Rates of infection appear similar in patients with solid tumours before and after they receive immune checkpoint inhibitor (ICI) therapy. A retrospective study from the Canberra Hospital assessed infection rates in 327 patients who commenced ICIs between 2012 and 2019. Patients were mainly being treated for metastatic disease in melanoma (47%) and NSCLC (36%) and ...
Reassurance on infection risk with checkpoint inhibitors
By Mardi Chapman
19 Nov 2020